These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22928490)

  • 1. Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.
    Valkhoff VE; van Soest EM; Masclee GM; de Bie S; Mazzaglia G; Molokhia M; Kuipers EJ; Sturkenboom MC
    Aliment Pharmacol Ther; 2012 Oct; 36(8):790-9. PubMed ID: 22928490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.
    Sukel MP; van der Linden MW; Chen C; Erkens JA; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):9-19. PubMed ID: 17963198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases.
    van Soest EM; Valkhoff VE; Mazzaglia G; Schade R; Molokhia M; Goldstein JL; Hernández-Díaz S; Trifirò G; Dieleman JP; Kuipers EJ; Sturkenboom MC
    Gut; 2011 Dec; 60(12):1650-9. PubMed ID: 21636644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of interventions by community pharmacists to reduce risk of gastrointestinal side effects in nonselective nonsteroidal anti-inflammatory drug users.
    Teichert M; Griens F; Buijs E; Wensing M; De Smet PA
    Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):382-9. PubMed ID: 24535837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
    Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
    Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
    Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What therapies have replaced rofecoxib in Ireland?
    Teeling M; O'Connor H; Feely J; Bennett K
    Br J Clin Pharmacol; 2007 Oct; 64(4):536-41. PubMed ID: 17555468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
    Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
    Schneeweiss S; Glynn RJ; Avorn J; Mamdani M; Mogun H; Solomon DH
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1134-42. PubMed ID: 19844943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    van der Veen WJ; van der Werf GT
    Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.